Month: April 2026

Kane Biotech Presents revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Spring Conference

Written by Customer Service on April 16, 2026. Posted in Public Companies.

>20 year‑old venous leg ulcers show dramatic healing and pain elimination with revyve Thermoreversible revyve transforms deep tunneling wound care, delivering 90% wound volume reduction revyve rapidly normalizes chronic wound pH, driving accelerated healing in weeksWINNIPEG, Manitoba, April 16, 2026 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces that Dr. Miloslav Sailer, External R&D Leader, presented at the Symposium on Advanced Wound Care (“SAWC”) Spring conference held from April 8-12, 2026 in Charlotte, North Carolina. At this year’s conference, Kane Biotech shared case study data on how revyve can help patients with complex chronic non-healing as well as clinical mechanistic investigations. The link to the presentations can be found here and...

Exodus Expands XRP and RLUSD Support, in Collaboration with Ripple

Written by Customer Service on April 16, 2026. Posted in Public Companies.

Deepening self-custody collaboration with native XRPL support OMAHA, Neb., April 16, 2026 (GLOBE NEWSWIRE) — Exodus Movement, Inc. (NYSE: EXOD) today announced expanded native support for the public blockchain XRP Ledger (XRPL) inside the Exodus wallet, deepening the in-wallet experience for one of the platform’s most actively used digital assets. As part of the expansion, Exodus is rolling out tools for managing and sending XRP (the native digital asset of the XRPL) directly from the Exodus wallet. In collaboration with Ripple, Exodus will also provide additional in-wallet support for Ripple USD (RLUSD), a trusted, enterprise-grade stablecoin designed with regulatory compliance, utility, and transparency at its core. XRP ranks among the leading assets in the Exodus wallet by user activity and swap volume. The expanded integration...

Guardian Capital Announces April 2026 Cash Distributions for Guardian Capital ETFs

Written by Customer Service on April 16, 2026. Posted in Dividend Reports And Estimates.

TORONTO, April 16, 2026 (GLOBE NEWSWIRE) — Guardian Capital LP (the “Manager”) announces the following regular cash distributions for the period ending April 30, 2026, in respect of the ETF series of the Guardian Capital funds listed below (the “Guardian Capital ETFs”). In each case, the distribution will be paid on April 30, 2026 to unitholders of record on April 24, 2026. The ex-dividend date in each case is anticipated to be April 24, 2026.Guardian Capital ETFs Series of ETF Units DistributionFrequency TradingSymbol Exchange Distribution Amount(per ETF Unit)GuardBondsTM 2026 Investment Grade Bond Fund ETF Units Monthly GBFC Cboe Canada CAD$0.0249GuardBondsTM 2027 Investment Grade Bond Fund ETF Units Monthly GBFD Cboe Canada CAD$0.0267GuardBondsTM 2028 Investment Grade Bond Fund ETF Units Monthly GBFE Cboe Canada CAD$0.0310GuardBondsTM...

Plato Gold Corp. Announces the Closing of the Sale of Timmins-Area Properties to Mayfair Gold Corp.

Written by Customer Service on April 16, 2026. Posted in Public Companies.

TORONTO, Ontario, April 16, 2026 (GLOBE NEWSWIRE) — Plato Gold Corp. (TSX-V: PGC) (OTCQB: NIOVF) (Frankfurt: 4Y7 or WKN: A0M2QX) (“Plato” or the “Company”) announces that it has closed the transaction (the “Transaction”) annouced on April 2, 2026 with Mayfair Gold Corp. (“Mayfair”) pursuant to which Mayfair has acquired Plato’s interests in the Guibord, Marriott and Holloway properties (collectively, the “Properties”), all located in the Timmins, Ontario area, for total cash consideration of C$2.5 million (the “Cash Consideration”). The Cash Consideration has been placed into escrow, as further described in this news release. The Properties consist of mineral claims and mining leases located along and adjacent to the Destor–Porcupine structural corridor in the Timmins gold district. The transaction allows Plato to monetize non‑core...

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

Written by Customer Service on April 16, 2026. Posted in Mergers And Acquisitions.

Company entered into an asset purchase agreement with Johnson & Johnson (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) MeiraGTx intends to immediately pursue global regulatory filings for approval of bota-vecLONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) — MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that it has entered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests in bota-vec for the treatment of XLRP. “We are extremely pleased to have reacquired bota-vec for the treatment of XLRP,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. “This is a unique opportunity to gain an...

Manhattan Bridge Capital, Inc. Reports First Quarter Results for 2026

Written by Customer Service on April 16, 2026. Posted in Earnings Releases And Operating Results.

GREAT NECK, N.Y., April 16, 2026 (GLOBE NEWSWIRE) — Manhattan Bridge Capital, Inc. (Nasdaq: LOAN) (the “Company”) announced today that its net income for the three months ended March 31, 2026 was approximately $1,274,000, or $0.11 per share (based on approximately 11.4 million weighted-average outstanding common shares), compared to approximately $1,373,000, or $0.12 per share (based on approximately 11.4 million weighted-average outstanding common shares) for the same period in 2025, representing a decrease of $99,000, or 7.2%. The decrease was primarily attributable to lower revenue, partially offset by reduced interest expense, reflecting lower average borrowings under the Company’s credit facility and decreased prevailing SOFR rates. Total revenues for the three months ended March 31, 2026 were approximately $2,068,000, compared...

Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency

Written by Customer Service on April 16, 2026. Posted in Public Companies.

EMERYVILLE, Calif., April 16, 2026 (GLOBE NEWSWIRE) — Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced a publication in Nature Structural & Molecular Biology highlighting the discovery and detailed characterization of MG119-28, a compact CRISPR nuclease with superior editing efficiency relative to previously identified compact nucleases. The publication, titled “Comparative characterization of Cas12f orthologs reveals mechanistic features underlying enhanced genome editing efficiency” highlights the potential of MG119-28 (formally named Al3Cas12f) to overcome low editing efficiency in mammalian systems of previously identified compact nucleases from the Cas12f class. The...

Abaxx to Launch World’s First Exchange-Traded Solar Futures Contract

Written by Customer Service on April 16, 2026. Posted in Public Companies.

Developed in partnership with Enwex, the contract introduces an exchange-cleared benchmark for hedging weather-driven volume risk in Germany’s expanding solar fleet TORONTO, April 16, 2026 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (CBOE:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, indirect majority shareholder of Abaxx Singapore Pte Ltd. (“Abaxx Singapore”), the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), and producer of the SmarterMarkets™ Podcast, today announced that Abaxx Exchange will expand its weather-indexed product suite with the launch of Enwex Germany Solar (GSM) futures, available for trading on April 23, 2026. For the first time in 2025, solar power produced more electricity in Germany than...

Adlai Nortye Announces $150.0 Million Private Placement Equity Financing

Written by Customer Service on April 16, 2026. Posted in Public Companies.

SINGAPORE and NORTH BRUNSWICK, N.J., April 16, 2026 (GLOBE NEWSWIRE) — Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $150.0 million, before deducting placement agent fees and other private placement expenses. The oversubscribed transaction includes participation from both new and existing institutional investors. New investors include Soleus Capital, Perceptive Advisors, ADAR1 Capital Management, MPM BioImpact, Octagon Capital, Eventide Asset Management and Kalehua Capital, DAFNA Capital Management, etc., with additional participation...

Cielo Closes Strategic Asset Acquisition and Announces Intention to Appoint Chief Operating Officer and Chief Development Officer

Written by Customer Service on April 16, 2026. Posted in Mergers And Acquisitions.

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO THE UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, April 16, 2026 (GLOBE NEWSWIRE) — Cielo Waste Solutions Corp. (TSXV: CMC; OTCQB: CWSFF) (“Cielo” or the “Company”) is pleased to announce that it has closed the previously announced acquisition (the “Acquisition”) of certain proprietary project development and evaluation assets from CDL Biofuels Ltd. (“CDL Biofuels”), a subsidiary of Canadian Discovery Ltd. (“CDL”), pursuant to an asset purchase agreement dated April 15, 2026 (the “APA”). Transaction Overview Pursuant to the APA, Cielo acquired from CDL Biofuels a suite of proprietary, non-public project development and evaluation assets, including databases, data sets, models, analytical tools, technical reviews, and related intellectual property...

Month: April 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals